At what enterprise value was ORGANOX acquired in 2025?

During the acquisition of ORGANOX by TERUMO in 2025, the company was valued at an estimated revenue multiple of 10x - 18x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of ORGANOX when it was acquired by TERUMO?

The estimated EV/EBITDA multiple for ORGANOX is in the range of Above 20x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was ORGANOX acquired by TERUMO?

ORGANOX was acquired by TERUMO in 2025.

What was the revenue of ORGANOX at the time of the deal?

The revenue of ORGANOX at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of ORGANOX during the acquisition?

ORGANOX's EBITDA is estimated to be in the range of 10M - 30M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the ORGANOX acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the ORGANOX deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.organox.com/news/terumo-to-acquire-organox-limited-a-leading-innovator-in-organ-preservation-devices-marking

← DATABASE

Home Database Healthcare & PharmaORGANOX

08/2025

ORGANOX acquired by TERUMO

UNITED KINGDOM Life Sciences / Medical Devices EV 1b - 4b EUR

Context

Lauxera Capital Partners has successfully finalized the divestment of its minority equity stake in UK-based OrganOx to Japanese medical giant Terumo, marking the first historical exit for the medtech-focused growth investor. Since its initial entry into OrganOx’s capital by leading a £25 million funding round in 2023, followed by co-leading a $142 million expansion round in February 2025 alongside HealthQuest, Lauxera has successfully driven a five-fold increase in OrganOx’s revenue base within a two-year holding period. This rapid scale-up has generated a highly lucrative return on investment of over 100% for the growth sponsor. Strategically, this high-profile realization is positioned to significantly accelerate the institutional fundraising momentum for Lauxera’s second flagship vehicle, which targets €400 million with a hard cap of €500 million.

It is worth noting that the fund Lauxera took control of Organox through an LBO in 2023.

ORGANOX, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level LOGIN than the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

OrganOx is a UK-based company founded in 2008, originating from the University of Oxford, which markets a groundbreaking device that can keep a liver graft functional outside the human body for up to 24 hours, significantly increasing the number of grafts eligible for transplantation. With innovative technology and a dedicated team, OrganOx has become a major player in the transplantation field, with a steadily growing revenue and established profitability, having generated a profit of £7.5 million in 2024. The company provides cutting-edge solutions to improve transplantation outcomes and meet the growing needs of patients. OrganOx is a success story in the medtech sector, with a history marked by strategic partnerships and targeted investments, such as the £25 million funding round led by Lauxera in 2023, and the $142 million funding round co-led by HealthQuest and Lauxera last February.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Other operations with ORGANOX

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
07/2023	LAUXERA	ORGANOX	UNITED KINGDOM	Life Sciences	Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 100M - 200M EUR

EBITDA range: 10M - 30M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ORGANOX by TERUMO are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: organox

Acquirer: terumo